Reliance in MD regulation - MTIIR, IMoH

Anat Boehm-Cagan Head of Regulatory Strategy and Partnerships, Medical Technology Directorate, Ministry of Health, Israel March 11, 2024



Reliance in pre-market processes

- Reliance is used for class I and II (IIa & IIb) products that have been registered and marketed in recognized countries
- Reliance pathways allow for shorter review time for:
 - Market approval (MA)
 - Significant changes
 - Renewal and non-significant changes declaration
- The MD validity is registered in accordance with recognized country MA
- Labeling is approved in accordance with recognized country MA







Reliance in post-market processes

- In general, reliance is based on requirement for MA holder (MAH) to report of any incidents (e.g., FSN, FSCA, recall) that accord in a recognized country.
- Other PM Information sources:
 - Reporting of local health organizations and patients
 - Public reporting of incidents from recognized countries
 - Specific RFIs from recognized countries





Key considerations with reliance

- Multiple countries -> multiple regulatory schemes
- Requirements from MAH versus manufacturer
- Timing of reporting (initial signal or after full investigation)









United States of America

2024